Cargando…

Clinical Implications of Plasma Epstein–Barr Virus DNA in Children and Adolescent Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy

Background: Plasma Epstein–Barr virus (EBV) DNA has been determined as a prognostic factor in adult nasopharyngeal carcinoma (NPC) patients. This study was designed to evaluate the prognostic value of plasma pretreatment EBV DNA in children and adolescent NPC patients receiving intensity-modulated r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Wenze, Lv, Xing, Guo, Xiang, Yuan, Yawei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136458/ https://www.ncbi.nlm.nih.gov/pubmed/32296633 http://dx.doi.org/10.3389/fonc.2020.00356

Ejemplares similares

Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma
por: Prayongrat, Anussara, et al.
Publicado: (2017)

Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma
por: Hau, Pok Man, et al.
Publicado: (2020)

Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy
por: Zhang, Lu, et al.
Publicado: (2015)

Exploring the Optimal Chemotherapy Strategy for Locoregionally Advanced Children and Adolescent Nasopharyngeal Carcinoma Based on Pretreatment Epstein-Barr Virus DNA Level in the Era of Intensity Modulated Radiotherapy
por: Zeng, Ziyi, et al.
Publicado: (2021)

Plasma Circulating Tumor Epstein–Barr Virus for the Surveillance of Cancer Progression in Bone-Only Metastatic Nasopharyngeal Carcinoma
por: Liu, Guo-Ying, et al.
Publicado: (2022)

Prognostic Value of Plasma Epstein-Barr Virus DNA Levels Pre- and Post-Neoadjuvant Chemotherapy in Patients With Nasopharyngeal Carcinoma
por: Zhu, Lisheng, et al.
Publicado: (2021)

Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy
por: Peng, Hao, et al.
Publicado: (2016)

The plasma Epstein–Barr virus DNA level guides precision treatment for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a large population-based cohort study from an endemic area
por: Liang, Hu, et al.
Publicado: (2018)

Half-Brain Delineation for Prediction of Radiation-Induced Temporal Lobe Injury in Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy
por: Du, Qing-Hua, et al.
Publicado: (2021)

Epstein-Barr Virus BART Long Non-coding RNAs Function as Epigenetic Modulators in Nasopharyngeal Carcinoma
por: Verhoeven, Rob J. A., et al.
Publicado: (2019)

Prognostic Value of Plasma Epstein–Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
por: Chen, Wen-Hui, et al.
Publicado: (2016)

Epstein-Barr virus and nasopharyngeal carcinoma
por: Young, Lawrence S., et al.
Publicado: (2014)

Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma
por: Chan, K.C. Allen
Publicado: (2014)

Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinoma
por: Hutajulu, Susanna Hilda, et al.
Publicado: (2014)

Tumor residue in patients with stage II–IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein–Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose
por: Huang, Ying-Ying, et al.
Publicado: (2023)

The Prognostic Impact of Combined Tumor-Infiltrating Lymphocytes and Pretreatment Blood Lymphocyte Percentage in Locally Advanced Nasopharyngeal Carcinoma
por: Cai, Zhuochen, et al.
Publicado: (2022)

The role of Epstein–Barr virus in nasopharyngeal carcinoma
por: Su, Zhi Yi, et al.
Publicado: (2023)

Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus–Related Nasopharyngeal Carcinoma
por: Li, Wang-Zhong, et al.
Publicado: (2021)

A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma
por: Qiu, Wen-Ze, et al.
Publicado: (2017)

Prognostic value of plasma Epstein–Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy
por: Li, Wen-Fei, et al.
Publicado: (2017)

The Effect of Prolonged Duration of Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma
por: Hua, Yi-Jun, et al.
Publicado: (2021)

Epstein–Barr Virus in Gliomas: Cause, Association, or Artifact?
por: Akhtar, Saghir, et al.
Publicado: (2018)

The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma
por: Li, You Quan, et al.
Publicado: (2018)

Role of Epstein-Barr Virus in the Development of Nasopharyngeal Carcinoma
por: Zhang, Hui, et al.
Publicado: (2017)

Epstein-barr virus detection in nasopharyngeal carcinoma-implications in a low-risk area
por: Breda, Eduardo, et al.
Publicado: (2015)

Positivity of both plasma Epstein–Barr virus DNA and serum Epstein–Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma
por: Zhao, Fei-Peng, et al.
Publicado: (2014)

Association Between Serum Cotinine Level and Serological Markers of Epstein–Barr Virus in Healthy Subjects in South China Where Nasopharyngeal Carcinoma Is Endemic
por: Yang, Qian-Yi, et al.
Publicado: (2019)

Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy
por: Peng, Hao, et al.
Publicado: (2016)

Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma
por: Ha, Joo Young, et al.
Publicado: (2020)

Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma
por: Cai, Qingqing, et al.
Publicado: (2019)

Editorial: Epstein-Barr virus and its contribution to pediatric tumors
por: Chabay, Paola, et al.
Publicado: (2022)

Identification and validation of an immunological microenvironment signature and prediction model for epstein-barr virus positive lymphoma: Implications for immunotherapy
por: Yao, Chenjiao, et al.
Publicado: (2022)

Radiomics for Diagnosis and Radiotherapy of Nasopharyngeal Carcinoma
por: Zhang, Yu-mei, et al.
Publicado: (2022)

Human Leukocyte Antigens and Epstein–Barr Virus-Associated Nasopharyngeal Carcinoma: Old Associations Offer New Clues into the Role of Immunity in Infection-Associated Cancers
por: Su, Wen-Hui, et al.
Publicado: (2013)

Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma
por: Li, Xiaoyu, et al.
Publicado: (2022)

The impact of plasma epstein–barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study
por: Tang, L-Q, et al.
Publicado: (2014)

Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population
por: Chen, Wen-Jie, et al.
Publicado: (2021)

Detecting plasma Epstein-Barr virus DNA to diagnose postradiation nasopharyngeal skull base lesions in nasopharyngeal carcinoma patients: a prospective study
por: Liang, Fa-Ya, et al.
Publicado: (2012)

Multivariate NTCP Model of Hypothyroidism After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma
por: Shen, Guanzhu, et al.
Publicado: (2021)

Second Primary Lung Adenocarcinoma After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma
por: Xue, Fen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cmtth6uhos97r63fkk52296ljl